A Phase III Multicenter Randomized Double-Blind Placebo-Controlled Parallel-Group Efficacy and Safety Study of Crenezumab in Patients with Prodromal to Mild Alzheimer's Disease
M
Martin Farlow, MD
Primary Investigator
J
Jessica MacLean
Primary Investigator
Overview
The purpose of this study is to compare the effects, good or bad, of crenezumab versus placebo (an inactive substance that looks like crenezumab).
Description
The purpose of this study is to evaluate crenezumab 60mg/kg compared with placebo when administered by intravenous (IV) infusion every 4 weeks over 100 weeks as measured by the global outcomes, as assessed by the Clinical Dementia Rating-Sum of Boxes at final outcome assessment at Week 105, 4 weeks after final dose.
Eligibility
You may be eligible for this study if you meet the following criteria:
-
Conditions:
Alzheimer's disease
-
Age: Between 50 Years - 85 Years
-
Gender: All
Updated on
20 Nov 2022.
Study ID: 1602730427
